Norgine B.V. completes acquisition of Merus Labs International Inc.

Date closed: 7/17/2017

Value: C$342 million

On July 17, 2017, Norgine B.V. (Norgine) completed the acquisition of Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) (Merus) pursuant to which Norgine acquired all of the issued and outstanding common shares of Merus and shareholders of Merus received cash consideration equal to C$1.65 per Share for a total consideration of approximately C$342 million.

Norgine, headquartered in Amsterdam, The Netherland, is a leading European specialist pharmaceutical with a direct commercial presence in all major European markets.

Merus, headquartered in Toronto, Ontario, is a specialty pharmaceutical company.

BLG is acting for Clarus Securities Inc., as financial advisor to Merus, with a team led by Andrew Powers.

For more information, please contact:

Kate Gifford
Borden Ladner Gervais LLP
KGifford@blg.com
416.350.6540

BLG | Canada’s Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 800 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

blg.com

© 2026 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.